Table 1.
Promiscuous Ligand Recognition by FPRs.
Source Diseases | Agonists | FPR1 | FPR2 | FPR3 |
---|---|---|---|---|
(Fpr1) | (Fpr2) | (Fpr3) | ||
Bacteria Infection | fMLF (E. Coli) | ++++ | ++ | |
Listeria peptides | ++++ | +++ | ||
Stomach cancer | Hp(2-20) | - | +++ | ++ |
Host Inflammation | Serum amyloid A | - | ++++ | |
Alzheimer’s | Aβ42, Humanin | + | ++++ | |
Prion disease | Prp106-126 | - | +++ | |
Angiogenesis | Annexin 1(ANXA1) | ++ | +++ | ++ |
Tissue damage | Mitochondria pep | +++ | +++ | |
F2 L (Heme) | - | ++ | ++++ | |
Coagulation | uPAR frag | - | +++ | |
Host defense | LL37 (CRAMP) | - | +++ | |
Cathepsin G | +++ | |||
Cancer | ANXA1 | ++ | +++ |
+ Denotes the relative potency of the ligands to activate a given FPR References: 1, 2, 16).